Mama's Creations, Inc. (MAMA) delivered earnings and revenue surprises of +66.67% and +1.87%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Mama's Creations, Inc. (MAMA) delivered earnings and revenue surprises of +66.67% and +1.87%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Intel (NASDAQ:INTC), which designs and manufactures semiconductor products, including CPUs and GPUs, closed Monday at $110.27, up 11.19%. The stock moved higher as reports highlighted a major Google AI chip order and potential foundry roles with Google and Nvidia. Investors are w
Intel (NASDAQ:INTC), which designs and manufactures semiconductor products, including CPUs and GPUs, closed Monday at $110.27, up 11.19%. The stock moved higher as reports highlighted a major Google AI chip order and potential foundry roles with Google and Nvidia. Investors are w
S&P 500 (SNPINDEX:^GSPC) rose 0.30% to 7,405.73 and the Nasdaq Composite (NASDAQINDEX:^IXIC) climbed 0.86% to 25,929.66 as tech stocks began to recover from Friday’s rout. The Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.16% to 50,786.01 as cyclicals lagged.
S&P 500 (SNPINDEX:^GSPC) rose 0.30% to 7,405.73 and the Nasdaq Composite (NASDAQINDEX:^IXIC) climbed 0.86% to 25,929.66 as tech stocks began to recover from Friday’s rout. The Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.16% to 50,786.01 as cyclicals lagged.
For the past several years, the market has associated Eli Lilly (NYSE: LLY) with one thing: obesity. Its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro have transformed the company, helping drive annual revenue from $34.1 billion in 2023 to more than $65.2 billion in 2025. But it would be foolish to ignore the elephant in the room: What's next after GLP-1 and obesity treatme...
For the past several years, the market has associated Eli Lilly (NYSE: LLY) with one thing: obesity. Its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro have transformed the company, helping drive annual revenue from $34.1 billion in 2023 to more than $65.2 billion in 2025. But it would be foolish to ignore the elephant in the room: What's next after GLP-1 and obesity treatments? Lilly may have just provided part of the answer. Image source: Getty Images. Continue reading
Never miss an episode. Follow The Big Take daily podcast today. The field for the 2026 US midterm elections is coming into focus, with key primaries this week in Maine and South Carolina, as well as bellwether state elections in California. On today’s Big Take podcast, hosts Sarah Holder and David Gura check in with political correspondent Nancy Cook and California reporter Eliyahu Kamisher about ...
Never miss an episode. Follow The Big Take daily podcast today. The field for the 2026 US midterm elections is coming into focus, with key primaries this week in Maine and South Carolina, as well as bellwether state elections in California. On today’s Big Take podcast, hosts Sarah Holder and David Gura check in with political correspondent Nancy Cook and California reporter Eliyahu Kamisher about what this week’s results — and the next five months — mean for midterm elections with the potential to profoundly shape US politics. We have a special Bloomberg subscription offer for podcast listeners at Bloomberg.com/podcastoffer. Listen and follow The Big Take on Apple Podcasts , Spotify or wherever you get your podcasts. Terminal clients: Visit NSUB to subscribe. This episode was produced by: Julia Press; Editors: Jeffrey Grocott; Fact-checker: Laura Newcombe; Sound Design/Engineer: Alex Sugiura; Senior Producer: Naomi Shavin; Senior Editor: Elisabeth Ponsot; Deputy Executive Producer: Julia Weaver; Executive Producer: Nicole Beemsterboer.
Key PointsOil prices are highly sensitive to the conflict in the Middle East because the longer it lasts the longer traffic will remain depressed in the Strait of Hormuz.
Key PointsOil prices are highly sensitive to the conflict in the Middle East because the longer it lasts the longer traffic will remain depressed in the Strait of Hormuz.
Campbell's CEO Serves Up Warning For Restaurants As "Resilient" At-Home Cooking Trend Gains Steam There is not much to get excited about in canned-soup maker Campbell's third-quarter results, with sales slumping and softness in its snack unit weighing on performance. But one revealing detail from management's earnings call earlier on Monday offers a broader read-through on the consumer: households...
Campbell's CEO Serves Up Warning For Restaurants As "Resilient" At-Home Cooking Trend Gains Steam There is not much to get excited about in canned-soup maker Campbell's third-quarter results, with sales slumping and softness in its snack unit weighing on performance. But one revealing detail from management's earnings call earlier on Monday offers a broader read-through on the consumer: households may be spending much more time cooking at home and pulling back from restaurants in the second half of the year. The canned-soup maker reaffirmed its full-year outlook, but Wall Street analysts were muted on the third-quarter results. BNP Paribas Max Gumport told clients that two key concerns remain: Campbell's ability to stabilize organic sales in the snack unit and to navigate another year of elevated inflation. He noted the quarterly beat was driven largely by SG&A and below-the-line items, while the guidance reaffirmation was partly supported by an expected fourth-quarter tariff refund benefit. Third-quarter adjusted EPS printed at 50 cents, beating the 48-cent Bloomberg Consensus estimate but down from 73 cents in the same period one year ago. Net sales fell 4.4% to $2.37 billion, slightly below estimates. Organic net sales declined 4%, worse than the 3.3% drop analysts tracked by Bloomberg expected, with both meals & beverages and snacks down 4%. Margins remained pressured. RBC Capital analyst Nik Modi said, "The company is navigating a challenging environment marked by inflation-driven margin headwinds and tariff impacts, which compressed adjusted gross margins by -240 bps points." Campbell's still expects full-year adjusted EPS of $2.15 to $2.25, versus the Bloomberg Consensus of $2.17, and organic net sales to fall 1% to 2%, versus the estimate of -2.14%. Notice how Campbell shares were crushed in the era of food inflation. After the earnings release, Campbell's held an analyst call. David Palmer, senior managing director and head of restaurant and food producers ...
OpenAI filed confidentially for an IPO, as the ChatGPT maker looks to join artificial intelligence rivals tapping public markets to fund ambitious growth plans. The Sam Altman -led firm submitted paperwork for an initial public offering with the US Securities and Exchange Commission, the company said. OpenAI is working with Goldman Sachs Group Inc. and Morgan Stanley on a potential listing as soon...
OpenAI filed confidentially for an IPO, as the ChatGPT maker looks to join artificial intelligence rivals tapping public markets to fund ambitious growth plans. The Sam Altman -led firm submitted paperwork for an initial public offering with the US Securities and Exchange Commission, the company said. OpenAI is working with Goldman Sachs Group Inc. and Morgan Stanley on a potential listing as soon as in the fall, people familiar with the matter have said . Deliberations are ongoing and details of the IPO plan could change. “We have not decided on timing yet; it may be a while because there are things we want to do that are likely easier as a private company,” the company said. “But it’s a complicated set of tradeoffs and this gives us the option to go public sooner if that ends up being best.” Founded more than a decade ago, OpenAI kicked off the generative AI boom with the release of ChatGPT in late 2022. Though the company and its flagship chatbot remain synonymous with AI for many people, OpenAI also faces a number of challenges, including heightened competition from Anthropic PBC and Alphabet Inc. ’s Google. OpenAI reportedly missed certain internal revenue and user growth targets. Several key executives have departed or stepped back from their roles. And the company has been working to streamline its sprawling product lineup. A public debut in 2026 would also pit Altman squarely against Elon Musk on a different plane than the failed lawsuit against OpenAI and its CEO. SpaceX, Musk’s rocket, satellite and AI firm, is targeting an IPO raising more than $75 billion at a more than $2 trillion valuation as soon as June, Bloomberg News has reported. Read More: SpaceX Is Planning to Buy Startup Cursor 30 Days After IPO OpenAI has already dwarfed even SpaceX’s IPO in a single funding round. The company completed a deal to raise $122 billion from investors at an $852 billion valuation. AI companies are racing to raise tens of billions of dollars to buy chips and data ce...